Table 1.

Selected Phase III Clinical Studies of Systemic Therapies in Advanced and Metastatic Gastric Carcinoma

Treatment	Setting (line)	Patients (n)	ORR (%)	PFS (months)	OS (months)	Ref.
EOX/ECF/ECX/EOF vs FOLFOX/CAPOX/XP	1st	349 vs 653	42 vs 33 NS	6.6 vs 6.1 NS	10.5 vs 9.9 NS	16
DCF vs cisplatin/5-FU	1st	221 vs 224	37 vs 25 *P=0.01	5.6 vs 3.7 *P <0.001	9.2 vs 8.6 *P <0.02	17
Cisplatin/5-FU/LV vs oxaliplatin/5-FU/LV	1st	112 vs 106	25 vs 34	3.9 vs 5.8 NS	8.8 vs 10.7 NS	18
Trastuzumab/5-FU/cisplatin vs 5-FU/cisplatin	1st (HER2 amplified)	298 vs 296	47 vs 35 *P <0.01	6.7 vs 5.5 *P <0.01	13.8 vs 11.1 *P <0.01	4
Ram vs placebo	2nd	238 vs 117	3.4 vs 2.6	2.1 vs 1.3 *P <0.01	5.2 vs 3.8 *P <0.05	19
Ram/Pac vs placebo/Pac	2nd	330 vs 335	28 vs 16 *P <0.01	4.40 vs 2.86 *P <0.01	9.63 vs 7.36 *P <0.05	20
Trifluridine/tipiracil vs placebo	3rd	337 vs 170	4 vs 2	2.0 vs 1.8 *P <0.0001	5.7 vs 3.6 *P <0.01	13

Note:- *P, statistically significant P value.

Abbreviations: CAPOX, capecitabine, oxaliplatin; DCF, docetaxel/cisplatin/5-fluorouracil; ECF, epirubicin/cisplatin/5-fluorouracil; ECX, epirubicin/cisplatin/capecitabine; EOF, epirubicin/oxaliplatin/5-fluorouracil; EOX, epirubicin/oxaliplatin/capecitabine; FOLFOX, folinic acid/5-fluorouracil/oxaliplatin; 5-FU, 5-fluorouracil; HER2, human epidermal growth factor receptor 2; LV, leucovorin; Pac, paclitaxel; Ram, ramucirumab; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; XP, capecitabine/cisplatin.